Sudeep Pharma Limited has submitted a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding their Q2 FY2027 earnings call.
The company refers to their previous communications dated 21st October 2026 (intimation of earnings call) and 28th October 2026 (investor presentation). The audio recording of the earnings call conducted on 29th October 2026 has been uploaded to the company's official website at https://www.sudeeppharma.com/ and is accessible at the specific URL: https://www.sudeeppharma.com/wp-content/uploads/2026/10/10047831.mp3.
This submission is made in compliance with Regulation 30 of the SEBI Listing Regulations, 2015. The company has indicated that a transcript of the earnings call will be submitted separately at a future date.
The disclosure was signed by Dimple Mehta, Company Secretary & Compliance Officer (Membership No.: F13184), who digitally signed the document on 29th October 2026 at 18:08:28 IST.
Company identification details: CIN: L24231GJ1989PLC013141. Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India. Corporate Office: 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat, India.